We are committed to serving the best interests of our shareholders. The investor pages that follow are your resource for financial information about Catalyst Biosciences, Inc.
NASDAQ: CBIO$3.320.02 (0.60%)Aug 18, 20174:00 p.m. ET
Delayed at least 15 minutes
Data provided by Nasdaq. Minimum 15 minutes delayed.
Press ReleasesAugust 03, 2017Catalyst Biosciences Reports Second Quarter 2017 Financial Results and Provides Subcutaneous (SQ) Hemophilia Program UpdateJuly 06, 2017Financial Milestone Achieved in Catalyst’s Subcutaneous Factor IX ProgramJune 28, 2017Catalyst Biosciences’ Factor IX Granted Orphan Drug Designation in EuropeView all press releases »
Reverse Stock Split
|For the 1 for 15 Reverse Stock Split Tax Form, click here|
Targacept Special Dividend
|For the FAQ and additional information, click here.|
Catalyst Biosciences, Inc.
Red House Consulting, LLC